Automated preparation of whole blood–derived platelets suspended in two different platelet additive solutions and stored for 7 days

Background The A treus system ( T erumo BCT ) automates the preparation of blood components from whole blood donations. Intermediate platelet ( PLT ) products can be pooled manually or with the OrbiSac ( T erumo BCT ) and suspended in different PLT additive solutions ( PASs ) to obtain PLT concentrates ( PCs ). The aim of our study was to compare the in vitro PLT quality of PCs obtained with either the A treus 2 C + and the OrbiSac or the A treus 3 C and suspended in PAS‐II or PAS‐IIIM during storage for up to 7 days. Study Design and Methods We prepared eight PCs from buffy coats obtained with A treus 2 C +, pooled with the OrbiSac , and suspended in PAS‐II and eight PCs from interim PLT units obtained with the A treus 3 C and suspended either in PAS‐II or in PAS‐IIIM . We measured volume, PLT content, and mean PLT component and performed metabolic assays ( pH , glucose, lactate, pO 2 , and pCO 2 ) and flow cytometry analyses ( GPIb , GPIIbIIIa , GPIV , CD62P , CD 63, von W illebrand factor [vWF], fibrinogen, F actor V , and annexin V ). Results PCs prepared with the A treus 3 C showed lower volume and higher PLT concentration when compared with PCs prepared with the A treus 2 C + and the OrbiSac (p < 0.05). G lucose consumption rate and the expression of CD62P , CD 63, and vWF were lower in PCs suspended in PAS‐IIIM when compared with PCs suspended in PAS‐II (p < 0.05). Conclusion PCs prepared with the A treus 3 C and suspended in PAS‐IIIM preserve satisfactorily the in vitro PLT quality during 7‐day storage. PLT activation during a 7‐day storage period was lower when the storage solution was PAS‐IIIM in comparison with PAS‐II .